{{Rsnum
|rsid=1010
|Gene=VAMP8
|Chromosome=2
|position=85581859
|Orientation=minus
|GMAF=0.4467
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=VAMP8
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 32.7 | 46.0 | 21.2
| HCB | 43.3 | 43.3 | 13.4
| JPT | 33.6 | 49.6 | 16.8
| YRI | 15.1 | 52.1 | 32.9
| ASW | 29.8 | 36.8 | 33.3
| CHB | 43.3 | 43.3 | 13.4
| CHD | 47.7 | 39.4 | 12.8
| GIH | 42.6 | 43.6 | 13.9
| LWK | 19.4 | 51.9 | 28.7
| MEX | 37.9 | 43.1 | 19.0
| MKK | 22.6 | 50.3 | 27.1
| TSI | 35.3 | 47.1 | 17.6
| HapMapRevision=28
}}This SNP, located on chromosome 2 in a gene ([[VAMP8]]) associated with platelet activation, may be associated with early onset [[myocardial infarction]] (MI). The risk allele for this SNP (in dbSNP orientation) is [[rs1010]](G), with an odds ratio of 1.75 (CI: 1.17â€“2.62). {{PMID|16690874}}

Furthermore, this SNP is one of the 5 used by [[Celera]]'s genetic risk score (GRS) for coronary [[heart disease]] (CHD).

*[[rs20455]], in the [[KIF6]] gene
*[[rs3900940]], in the [[MYH15]] gene
*[[rs7439293]], in the [[PALLD]] gene
*[[rs2298566]], in the [[SNX19]] gene
*[[rs1010]], in the [[VAMP8]] gene

For each of the five variants, the GRS was increased by 1 if the subject was homozygous for the risk variant, unchanged if heterozygous, and decreased by 1 if the individual did not carry the variant. Therefore, individuals carrying all 10 possible risk variants (two copies of each of the five SNPs) were assigned a GRS of 5 and those carrying no risk variants a GRS of -5. A high GRS was defined as 3 or higher. Approximately 4% of the white cohort in ARIC was classified as high risk, and the hazard ratio for CHD after adjustment for traditional risk factors was a significant 1.57 (CI: 1.21-2.04; p<0.001). The results did not reproduce for African American participants.{{PMID|18073581}}

{{PharmGKB
|RSID=rs1010
|Name_s=
|Gene_s=VAMP8, VAMP5
|Feature=
|Evidence=PubMed ID:18073581
|Annotation=This variant is associated with an elevated risk of coronary heart diseases.
|Drugs=
|Drug Classes=
|Diseases=Coronary Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA161795948
}}

{{PMID Auto
|PMID=19752551
|Title=Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: vienna stroke registry
|OA=1
}}

{{PMID Auto
|PMID=22192511
|Title=KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly
}}

{{PMID Auto
|PMID=17767904
|Title=Genetic and genomic insights into the molecular basis of atherosclerosis.
|OA=1
}}

{{PMID Auto
|PMID=18599554
|Title=Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia.
|OA=1
}}

{{PMID Auto
|PMID=19374688
|Title=No influence of the VAMP8 rs1010 single nucleotide polymorphism on platelet functions in vitro.
}}

{{PMID Auto
|PMID=19943878
|Title=VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA.
|OA=1
}}

{{PMID Auto
|PMID=22676277
|Title=Vascular associated gene variants in patients with preeclampsia: results from the Danish National Birth Cohort
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1010
|overall_frequency_n=51
|overall_frequency_d=128
|overall_frequency=0.398438
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}